Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Quentin30on Dec 01, 2022 6:38pm
286 Views
Post# 35144806

Food for thought... increased attention

Food for thought... increased attentionTry running a Youtube search for Oncolytics Biotech... there are plenty of videos dating back to the dark ages of Brad Thomson, spewing all kinds of nonsense about seamless Phase III trials... pure BS in retrospect.

But those videos and Ellis Reports only have a few hundred views at best...

Roll on the latest interview with Matt a couple of weeks ago, and views are already numbering 3.7k... ten times those of previous years.

Hopefully this signals a shift of focus BACK to ONCY. Today's news was most welcome, but do remember that in one of those interviews from 2017, Matt is talking of having received Fast Track approval for mBC, and we know how long it's taken to get to running a Phase III from that... 

If history repeats, then tomorrow may start up, finish slightly down, and then continue dropping until after the poster presentations, only to drop back to where the run started. I hope I'm wrong this time, but long termers have seen this time and time again.

GLTA 
<< Previous
Bullboard Posts
Next >>